Kestra Medical Technologies (NASDAQ:KMTS) Trading Down 6% – What’s Next?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s share price was down 6% on Friday . The company traded as low as $24.75 and last traded at $25.05. Approximately 39,772 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 239,159 shares. The stock had previously closed at $26.65.

Wall Street Analyst Weigh In

Several research analysts recently commented on KMTS shares. Piper Sandler lifted their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. The Goldman Sachs Group reissued a “neutral” rating and set a $27.00 price objective on shares of Kestra Medical Technologies in a research report on Friday. BTIG Research began coverage on Kestra Medical Technologies in a report on Tuesday, November 18th. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Stifel Nicolaus set a $30.00 price target on Kestra Medical Technologies in a report on Friday, December 12th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $29.43.

Kestra Medical Technologies Trading Down 8.3%

The firm has a market cap of $1.43 billion and a P/E ratio of -7.71. The company’s 50 day moving average is $26.07 and its two-hundred day moving average is $21.87. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.47 and a quick ratio of 5.47.

Insider Buying and Selling

In related news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $26.59, for a total value of $398,850.00. Following the completion of the transaction, the insider directly owned 409,786 shares of the company’s stock, valued at $10,896,209.74. This trade represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Traci S. Umberger sold 10,500 shares of Kestra Medical Technologies stock in a transaction on Monday, December 29th. The stock was sold at an average price of $26.69, for a total transaction of $280,245.00. Following the sale, the insider owned 136,633 shares in the company, valued at $3,646,734.77. This represents a 7.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is currently owned by company insiders.

Institutional Trading of Kestra Medical Technologies

Several institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. acquired a new position in Kestra Medical Technologies in the third quarter worth about $48,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Kestra Medical Technologies in the 2nd quarter valued at approximately $54,000. BNP Paribas Financial Markets raised its holdings in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after buying an additional 1,638 shares in the last quarter. Brown Brothers Harriman & Co. lifted its position in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares during the period. Finally, New York State Common Retirement Fund acquired a new stake in Kestra Medical Technologies in the 2nd quarter valued at $93,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.